Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Jul 9, 2012
Best Buy Slashes 2,400 Jobs
Big box electronics retailer Best Buy announced that it will lay off 2,400 employees. We still aren't excited about the company. Jul 9, 2012
Informatica Lowers Guidance Again
Data software solutions provider Informatica lowered its second-quarter guidance for the second time this year. Shares continue to fall. Jul 9, 2012
Seagate Warns About Revenue and Earnings
Hard-drive storage manufacturer Seagate Technology will not meet its own expectations. The industry continues to recover from the flooding in Thailand. Jul 7, 2012
Can Navistar Make a Comeback?
Truck maker Navistar announced that it is ditching its diesel engine that failed to receive US regulatory approval in favor of a new one. The shares have fallen below the low end of our fair value range, but we're not ready to pull the trigger anytime soon. Jul 6, 2012
AutoNation and Volkswagen Report Good News
Car dealer AutoNation reported fantastic results for June and its second quarter. German auto manufacturer Volkswagen will finally acquire the rest of Porsche. Jul 6, 2012
International Speedway Posts Solid Results
The NASCAR racetrack owner posted strong results Thursday. The firm's middle class consumer is returning slowly. Jul 5, 2012
June Same Store Sales Actually Weren’t Bad
Though a few companies fell short of expectations, we thought June same-store sales numbers were mostly positive. We think lower energy prices may have reinvigorated the US consumer during the month. Jul 4, 2012
Strong Auto Sales Continue in June
Sales in the US remained strong throughout June. We think SAAR will remain above 14 million units for the remainder of 2012. Jul 3, 2012
Ancestry.com's Subscriber Growth Remains Strong
The online genealogy firm said that it added its 2 millionth active subscriber recently. We continue to expect ongoing subscriber expansion thanks to the release and digital indexing of the 1940 US Federal Census. Jul 2, 2012
Bristol-Myers Squibb and AstraZeneca Purchase Amylin
The two pharmaceutical companies will collaborate to commercialize the diabetes portfolio of Amylin. We think the deal is value neutral.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353354355356357358359360 361362363364365366367368369370371372373374375376377378379380 381382383384385386387388389390391392393394395396397398399400 401402403404405406407408409410411412413414415416417418419420 421422423424425426427428429430431432433434435436437438439440 441442443444445446447448449450451452453454455456457458459460 461462463464465466467468469470471472473474475476477478479480 481482483484485486487488489490491492493494495496497498499500 501502503504505506507508509510511512513514515516517518519520 521522523524525526527528529530531532533534535536537538539540 541542543544545546547548549550551552553554555556557558559560 561562563564565566567568569570571572573next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|